Meeting
2020 ASCO Virtual Scientific Program
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
Authors
Helen Gogas
First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Helen Gogas , Paolo Antonio Ascierto , Keith Flaherty , Ana Arance , Mario Mandalà , Gabriella Liszkay , Claus Garbe , Dirk Schadendorf , Ivana Krajsova , Ralf Gutzmer , Jan Willem de Groot , Caroline Dutriaux , Carmen Loquai , Ashwin Gollerkeri , Michael D Pickard , Caroline Robert , Reinhard Dummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01909453
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10012)
DOI
10.1200/JCO.2020.38.15_suppl.10012
Abstract #
10012
Poster Bd #
361
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Update on Overall Survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma.
First Author: Gabriella Liszkay
Poster
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2020 ASCO Virtual Scientific Program
Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.
First Author: Victoria Atkinson
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu